Evidence map›Paper›PMID 42289805›Full record

ArticleJournal of diabetes investigation2026

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data.

Tomoe Abe, Fumika Maruyama, Eisuke Nishikawa, Miki Ito, Yukie Miyano, Hiroki Yamagata, Taiga Sasaki, Hidemitsu Sakagami, Akinobu Nakamura, Hiroshi Nomoto and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tomoe AbeSapporo Diabetes and Thyroid Clinic, Sapporo, Hokkaido, Japan.
Fumika MaruyamaDivision of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Eisuke NishikawaDivision of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Miki ItoKurihara Clinic, Sapporo, Hokkaido, Japan.
Yukie MiyanoSapporo Diabetes and Thyroid Clinic, Sapporo, Hokkaido, Japan.
Hiroki YamagataDepartment of Diabetology and Endocrinology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Hokkaido, Japan.
Taiga SasakiDepartment of Diabetology and Endocrinology, Asahikawa City Hospital, Asahikawa, Hokkaido, Japan.
Hidemitsu SakagamiDepartment of Diabetology and Endocrinology, Asahikawa City Hospital, Asahikawa, Hokkaido, Japan.
Akinobu NakamuraDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.ORCID https://orcid.org/0000-0002-8192-0006
Hiroshi NomotoDivision of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.ORCID https://orcid.org/0000-0003-0713-221X
Hokkaido‐TZP Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although tirzepatide efficaciously reduces glucose concentrations and weight, phase 3 trials evaluated patients with a body mass index (BMI) ≥23 kg/m

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsTirzepatideAgedBlood GlucoseBody Mass IndexEast Asian PeopleFemaleFollow-Up StudiesGlycated HemoglobinHumansJapanMaleMiddle AgedObesityPrognosisBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsTirzepatideNon‐obeseTirzepatideType 2 diabetes

Identifiers

PMID42289805
PMCPMC13399590

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.